Your session is about to expire
← Back to Search
Monoclonal Antibodies
Cosibelimab + Ublituximab + Bendamustine combination for Non-Hodgkin's Lymphoma
Phase 1
Waitlist Available
Research Sponsored by TG Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Histologically confirmed relapsed or refractory B-cell non-Hodgkin lymphoma (NHL).
Measurable disease and adequate organ function as specified in the protocol
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 12 months
Awards & highlights
Study Summary
This study is evaluating whether a new treatment may help individuals with Hodgkin's lymphoma.
Eligible Conditions
- Richter's Transformation
- Non-Hodgkin's Lymphoma
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 12 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 12 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Adverse Events That Are Related to Treatment
Secondary outcome measures
Overall Response Rate
Trial Design
3Treatment groups
Experimental Treatment
Group I: Cohort CExperimental Treatment1 Intervention
Cosibelimab + Ublituximab + Bendamustine combination
Group II: Cohort BExperimental Treatment1 Intervention
Cosibelimab + Ublituximab + Bendamustine combination
Group III: Cohort AExperimental Treatment1 Intervention
Cosibelimab (TG-1501) single-agent
Find a Location
Who is running the clinical trial?
TG Therapeutics, Inc.Lead Sponsor
36 Previous Clinical Trials
5,613 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger